ViaLase secures $40 million in Series C financing to advance femtosecond laser
Click Here to Manage Email Alerts
Key takeaways:
- ViaLase has completed $40 million in Series C financing.
- The funding will help advance development of the ViaLase femtosecond laser for the treatment of glaucoma.
ViaLase has secured approximately $40 million in Series C financing to drive the continued development of the company’s femtosecond laser for the treatment of glaucoma, according to a press release.
The financing was led by a new investor and supported by current investors, including Venture Investors Health Fund, Arboretum Ventures and Falcon Vision.
Image: Adobe Stock
The ViaLase laser is designed to help ophthalmologists precisely create channels in the trabecular meshwork through a “noninvasive, nonsurgical approach,” using femtosecond laser image-guided high-precision trabeculotomy, according to the press release. The funding will support ViaLase’s continued clinical, regulatory and commercial milestones.
"The strong support from our investors validates the potential of the ViaLase Laser to enhance the current treatment paradigm for the millions of patients living with glaucoma," Tibor Juhasz, PhD, founder and CEO of ViaLase, said in the release. "We are preparing to embark on a new phase in our company's evolution — commercialization — and are incredibly fortunate to have the support, resources, financial backing and counsel of such a high-caliber group of investors."
If approved, the ViaLase laser will be the first femtosecond laser used for the treatment of primary open angle glaucoma.
Read more about
Click Here to Manage Email Alerts